Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30077693 | 1.00 | LPL (0.33) | LPLLIPGEGFRMEN1ALDH1A1 | |
| SCHEMBL23569463 | 0.84 | LPL (0.34) | LPLLIPGALDH1A1 | |
| SCHEMBL25173250 | 0.82 | LPL (0.41) | LPLLIPG | |
| SCHEMBL30077847 | 0.82 | LPL (0.41) | LPLLIPG | |
| SCHEMBL21459066 | 0.80 | NQO2 (0.46) | LPLLIPGMEN1ALDH1A1MAPT | |
| SCHEMBL29414003 | 0.80 | NQO2 (0.46) | LPLLIPGMEN1ALDH1A1MAPT | |
| SCHEMBL29964335 | 0.78 | NQO2 (0.41) | LPLLIPGMEN1ALDH1A1MAPT | |
| SCHEMBL24176057 | 0.77 | ESR1 (0.34) | LPLLIPGEGFR | |
| SCHEMBL31270011 | 0.77 | ESR1 (0.34) | LPLLIPGEGFR | |
| SCHEMBL24373694 | 0.75 | MAOA (0.34) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-12-04 | — | — | US | disclosed |
| US-12378243-B2 | Quinoline compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-06-12 | — | — | US | disclosed |
| EP-4548918-A2 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20240368152-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2024-11-07 | — | — | US | disclosed |
| US-11939328-B2 | Quinoline compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230192696-A1 | SPIRO COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-06-22 | — | — | US | disclosed |
| US-20230144051-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11530218-B2 | Spiro compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210230162-A1 | SPIRO COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378243-B2 | Quinoline compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | LPL 4454/4885LIPG 3005/4885EGFR 1111/4885 |
| US-20240368152-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | LPL 4454/4885LIPG 3005/4885EGFR 1111/4885 |
| US-20230144051-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | LPL 4454/4885LIPG 3005/4885EGFR 1111/4885 |
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | LPL 4234/4885LIPG 2510/4885EGFR 460/4885 |
| US-20230192696-A1 | SPIRO COMPOUNDS AS INHIBITORS OF KRAS | KRAS, HRAS, NRAS | LPL 3800/4885LIPG 2661/4885EGFR 935/4885 |
| US-20210230162-A1 | SPIRO COMPOUNDS AS INHIBITORS OF KRAS | KRAS, HRAS, NRAS | LPL 3800/4885LIPG 2661/4885EGFR 935/4885 |
| US-11530218-B2 | Spiro compounds as inhibitors of KRAS | KRAS, HRAS, NRAS | LPL 3792/4885LIPG 2831/4885EGFR 672/4885 |
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | LPL 4454/4885LIPG 3005/4885EGFR 1111/4885 |
| US-11939328-B2 | Quinoline compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | LPL 4454/4885LIPG 3005/4885EGFR 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.